Lonza

Looking for your next opportunity? We’ve just launched our brand new careers site, designed to make finding and applying for your next role easier than ever. Whether you’re a seasoned professional or just starting out in the industry, you could make a difference here at Lonza. Explore our new careers site to: ▶️ Find varied roles across our global teams ▶️ Learn more about our company culture ▶️ Discover how we invest in employee growth ▶️ Join our talent community and keep in touch Visit Lonza.com/careers to see how you could make an impact with us.   #Careers #Hiring #JoinOurTeam 

We have just announced a collaboration with Iconovo for the formulation development of an intranasal biologic targeting obesity for Iconovo’s proprietary intranasal device ICOone Nasal®. The spray-dried formulation will be developed at our Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US). Kim Shepard, Director of Advanced Drug Delivery at Lonza, said: “Our team at Lonza’s respiratory center of excellence in Bend is pleased to work with Iconovo on its innovative applications, combining Lonza’s particle engineering expertise with Iconovo’s state-of-the-art devices. Delivering non-invasive and accessible therapies to patients in need is a focus area for both companies.” Read more about the collaboration here: https://lnkd.in/dbUxE7W2 #AHealthierWorld #PharmaceuticalManufacturing #SprayDrying #Biologics

Here at Lonza, we are well aware of the challenges facing our early-phase customers in meeting accelerated development timelines. Our experts use tools such as high-throughput experimentation and advanced model-based design of experiments to speed up process development in the early stages of a drug’s journey into the clinic. Our small molecule experts, Jens Schmidt and Nichola McCann, are giving a webinar where they’ll explain how we leverage these tools through detailed case studies. It’s taking place on Thursday 23 January at 5pm CET/11am EST, hosted by Life Science Connect, and is free to attend. You can register here https://lnkd.in/duxYu6Eb. Do join them to find out more. #LonzaSM #WeWorkAsOne #HTEWebinar

We wish you, your family and your loved ones a happy holiday season and great New Year. Thank you to all of our colleagues, partners and followers for a great 2024.

We have just announced capacity expansions at our sites in Rewari, India, and Suzhou, China. The expansions include additional hard gelatin capsule lines to support the manufacture of high-quality hard gelatin capsules, including essential and specialized capsules for the pharmaceutical and nutraceutical industries. The capacity expansion represents another step in the implementation of Lonza CHI’s hard empty capsules network strategy, focusing on long-term competitiveness and meeting the highest quality and sustainability standards. Read more: https://lnkd.in/dq4KzhPG #Capsules #Expansion #PharmaceuticalManufacturing

We have just opened our new R&D research laboratory at our site in Slough, UK. The new labs will provide an environment that is designed to foster collaboration and optimize our processes, enhancing our research capabilities. The space has been specifically designed to streamline workflows and enhance productivity, ensuring that our teams can focus on what they do best: groundbreaking research. #Biologics #Research #Biotechnology #PharmaceuticalManufacturing

Today's small molecule cancer drugs are more complex than ever, introducing new chemistry, manufacturing and control (CMC) challenges. At Lonza, we're proud to partner with our customers to overcome these challenges by developing scalable manufacturing processes and fine-tuned formulations. Our latest interactive C&EN article explores the transformative role of small molecule oncology drugs in cancer treatment and how researchers continue to identify new drug targets and more patient-friendly therapies. Furthermore, our Lonza expert Charlie Johnson shares his insights into how our industry-leading capabilities in computer-aided process design, high-throughput experimentation, solid form selection, and advanced pharmacokinetic modeling are helping our customers to drive innovation in oncology drug development. Read the full article here: https://bit.ly/3Di44br #LonzaSM #WeWorkAsOne

🔔Exciting news! The Lonza Small Molecules West Coast Business Development team will be in San Francisco Bay Area for J.P. Morgan Health Conference from January 13th to 16th, 2025. We look forward to discussing the latest innovations and future trends shaping the small molecules market, and can’t wait to engage with industry experts and thought leaders. 💻 Connect with us Tanner Call, Duke Chalker, Elizabeth Crofts to schedule a meeting.  💬 Let’s talk chemistry, drug development and manufacturing, and all things biotech/pharma. #AHealthierWorld #SmallMolecules #PharmaceuticalManufacturing #WeWorkAsOne

Biologics in Focus – December edition is ready for you to read. As we approach the New Year, we’re excited to share the latest updates shaping the future of biologics and wish you a holiday season filled with joy and relaxation. Some of this month’s highlights include: - A review of emerging biotechs and how they can accelerate early-stage development through partnerships - Updates on advancements in gene expression control with our enhanced GS® CHO Vector Technology - Expert insights into successful biologics tech transfers - A case study on Synaffix’s platform integration into BigHat’s AI-driven protein engineering to accelerate ADC development - The expansion of bioconjugation capabilities in Visp, Switzerland, with two new manufacturing suites to produce complex biotherapeutics like antibody-drug conjugates (ADCs). Join us in driving innovation and shaping the future of biologics in the coming year—one breakthrough at a time. #LonzaBio #Pharma #Biotechnology #ThePeoplePoweringBiologics #BiologicsInFocus

This morning, we announced our new “One Lonza” strategy to focus on our CDMO business, reshape our operating model, elevate execution in manufacturing and engineering, and expand through an impartial approach to buy and build. As we focus on our core CDMO business, we plan to exit the Capsules & Health Ingredients (CHI) business at an appropriate time and in the best interest of shareholders and stakeholders. Our CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. This simplified structure is designed to enhance customer experience, provide scalability for future growth and strengthen our multimodality offering. Learn more here: https://lnkd.in/dAZg2Z_3 #CDMO #StrategyUpdate #Lonza